切换导航
  • 比较产品
我的购物车

SepMate™-50(试管)

用于体外诊断（IVD）应用的密度梯度离心管
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #85450_C

用于体外诊断（IVD）应用的密度梯度离心管

产品优势

  • 无需在密度梯度介质上仔细分层血液（例如：lymphooprep™等）。
  • 减少总离心机时间到10分钟与制动新鲜样品
  • 通过简单地倒出上清，可以快速和容易地收获分离的单个核细胞
  • 能否与RosetteSep™浓缩鸡尾酒结合，在30分钟内分离特定细胞类型

产品组分包括

  • SepMate™-50 (IVD)， 100支（目录#85450）
    • 分配器盒包含4袋，25支/袋
  • SepMate™-50 (IVD)， 500支（目录#85460）
    • 分配器盒包含4袋，25管/袋（目录#85450）x 5
main product photo
Try SepMate™-50 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.
  1. Lymphoprep™
    Lymphoprep™

    Density gradient medium for the isolation of mononuclear cells

What Our Scientist Says

Traditional isolation of PBMCs requires careful layering of blood onto density gradient media prior to centrifugation. We developed SepMate™ to simplify this process, so anyone can isolate PBMCs with a simple pour while maintaining consistency across samples.

Peter MorinTechnical Scientist
Peter Morin, Technical Scientist
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

概述

通过将SepMate™纳入您的密度梯度离心步骤，简化外周血单个核细胞（PBMC）分离。

SepMate™管包含一个插入物，在密度梯度介质和血液之间形成屏障，从而消除了仔细分层血液的需要，并允许简单的倒液即可轻松收获单个核细胞。本品可与RosetteSep™分离特异性免疫细胞亚群。

SepMate™在cGMP下生产，并在澳大利亚、加拿大、欧洲和美国注册为体外诊断（IVD）设备。在中国，SepMate™被中国食品药品监督管理局（CFDA）视为非医疗器械，应作为一般实验室设备使用。最终用户负责确定产品是否适合他们的特定应用。

浏览我们的常见问题（FAQs）在SepMate™。

Contains

Polypropylene tube containing an insert
 
Subtype
Centrifugation Tubes
 
Cell Type
B Cells, Dendritic Cells, Monocytes, Mononuclear Cells, NK Cells, T Cells, T Cells, CD4+, T Cells, CD8+, T Cells, Other Subsets, T Cells, Regulatory
 
Species
Human
 
Sample Source
Bone Marrow, Whole Blood
 
Selection Method
Negative
 
Application
Cell Isolation, In Vitro Diagnostic
 
Brand
SepMate
 
Area of Interest
Chimerism, HLA, Immunology
 
查看更多 显示更少

Data Figures

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 1. Recovery of mononuclear cells (MNCs) from peripheral blood using SepMate™-50 versus standard density gradient centrifiguation. Recovery of MNCs from fresh and 48-hour post blood draw enriched by density gradient centrifugation with SepMate™ (purple) or without (grey). There was no significant difference in the recovery of MNCS with and without SepMate™.

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 2. Human CD4+ T Cell Isolation using SepMate™-50 and RosetteSep™ Human CD4+ T Cell Enrichment Cocktail

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
SepMate™-50 (IVD)
Catalog #
85450, 85460
Lot #
All
Language
MULTI

Resources and Publications

Educational Materials (13)

Lymphoprep™ Density Gradient Medium for Mononuclear Cell Isolation
Brochure
Lymphoprep™ Density Gradient Medium for Mononuclear Cell Isolation
SepMate™ Hassle-Free PBMCs in Just 15 Minutes
Brochure
SepMate™ Hassle-Free PBMCs in Just 15 Minutes
How to Isolate Mononuclear Cells from Blood in 15 Minutes with SepMate™
Protocol
How to Isolate Mononuclear Cells from Blood in 15 Minutes with SepMate™
How to Speed up Your PBMC Isolations with SepMate™
18:36
Video
How to Speed up Your PBMC Isolations with SepMate™
Cell Isolation in One Spin Using SepMate™ Tubes and RosetteSep™ Cell Separation Reagents
1:02
Video
Cell Isolation in One Spin Using SepMate™ Tubes and RosetteSep™ Cell Separation Reagents
How to Isolate PBMCs from Whole Blood Using the SepMate™ PBMC Isolation Tubes: 15-Minute Protocol
1:46
Video
How to Isolate PBMCs from Whole Blood Using the SepMate™ PBMC Isolation Tubes: 15-Minute Protocol
How SepMate™ PBMC Isolation Tubes Work: From Whole Blood to PBMCs in 15 Minutes
2:28
Video
How SepMate™ PBMC Isolation Tubes Work: From Whole Blood to PBMCs in 15 Minutes
Streamlining PBMC Isolation with Automation: A Biobank’s Validation Experience
51:35
Webinar
Streamlining PBMC Isolation with Automation: A Biobank’s Validation Experience
A Specialized Tube to Make Enrichment of Specific Cell Subsets Faster and Easier
Scientific Poster
A Specialized Tube to Make Enrichment of Specific Cell Subsets Faster and Easier
A Specialized Tube for Rapid PBMC Preparation, Pre-Enrichment, or Isolation of Specific Cell Populations
Scientific Poster
A Specialized Tube for Rapid PBMC Preparation, Pre-Enrichment, or Isolation of Specific Cell Populat...
Fast and Easy Hematopoietic Progenitor Cell Enrichment With SepMate™
Scientific Poster
Fast and Easy Hematopoietic Progenitor Cell Enrichment With SepMate™
A Specialized Tube to Make Rosettesep™ Enrichment of Specific Cell Subsets Faster and Easier
Scientific Poster
A Specialized Tube to Make Rosettesep™ Enrichment of Specific Cell Subsets Faster and Easier
Human Immune Cell Isolation Course
On-Demand Training
Human Immune Cell Isolation Course

Publications (44)

Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. K. H. Bhatt et al. The Journal of experimental medicine 2020 oct

Abstract

Cellular immunotherapeutics targeting the human papillomavirus (HPV)-16 E6 and E7 proteins have achieved limited success in HPV-positive oropharyngeal cancer (OPC). Here we have conducted proteome-wide profiling of HPV-16-specific T cell responses in a cohort of 66 patients with HPV-associated OPC and 22 healthy individuals. Unexpectedly, HPV-specific T cell responses from OPC patients were not constrained to the E6 and E7 antigens; they also recognized E1, E2, E4, E5, and L1 proteins as dominant targets for virus-specific CD8+ and CD4+ T cells. Multivariate analysis incorporating tumor staging, treatment status, and smoking history revealed that treatment status had the most significant impact on HPV-specific CD8+ and CD4+ T cell immunity. Specifically, the breadth and overall strength of HPV-specific T cell responses were significantly higher before the commencement of curative therapy than after therapy. These data provide the first glimpse of the overall human T cell response to HPV in a clinical setting and offer groundbreaking insight into future development of cellular immunotherapies for HPV-associated OPC patients.
View publication
The Effect of Bovine Viral Diarrhea Virus (BVDV) Strains and the Corresponding Infected-Macrophages' Supernatant on Macrophage Inflammatory Function and Lymphocyte Apoptosis. K. Abdelsalam et al. Viruses 2020 jun

Abstract

Bovine viral diarrhea virus (BVDV) is an important viral disease of cattle that causes immune dysfunction. Macrophages are the key cells for the initiation of the innate immunity and play an important role in viral pathogenesis. In this in vitro study, we studied the effect of the supernatant of BVDV-infected macrophage on immune dysfunction. We infected bovine monocyte-derived macrophages (MDM) with high or low virulence strains of BVDV. The supernatant recovered from BVDV-infected MDM was used to examine the functional activity and surface marker expression of normal macrophages as well as lymphocyte apoptosis. Supernatants from the highly virulent 1373-infected MDM reduced phagocytosis, bactericidal activity and downregulated MHC II and CD14 expression of macrophages. Supernatants from 1373-infected MDM induced apoptosis in MDBK cells, lymphocytes or BL-3 cells. By protein electrophoresis, several protein bands were unique for high-virulence, 1373-infected MDM supernatant. There was no significant difference in the apoptosis-related cytokine mRNA (IL-1beta, IL-6 and TNF-a) of infected MDM. These data suggest that BVDV has an indirect negative effect on macrophage functions that is strain-specific. Further studies are required to determine the identity and mechanism of action of these virulence factors present in the supernatant of the infected macrophages.
View publication
Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum. S. Phillips et al. Scientific reports 2020 jun

Abstract

Chlamydia infection and disease are endemic in free-ranging koalas. Antibiotics remain the front line treatment for Chlamydia in koalas, despite their rates of treatment failure and adverse gut dysbiosis outcomes. A Chlamydia vaccine for koalas has shown promise for replacing antibiotic treatment in mild ocular Chlamydia disease. In more severe disease presentations that require antibiotic intervention, the effect of vaccinating during antibiotic use is not currently known. This study investigated whether a productive immune response could be induced by vaccinating koalas during antibiotic treatment for Chlamydia-induced cystitis. Plasma IgG antibody levels against the C. pecorum major outer membrane protein (MOMP) dropped during antibiotic treatment in both vaccinated and unvaccinated koalas. Post-treatment, IgG levels recovered. The IgG antibodies from naturally-infected, vaccinated koalas recognised a greater proportion of the MOMP protein compared to their naturally-infected, unvaccinated counterparts. Furthermore, peripheral blood mononuclear cell gene expression revealed an up-regulation in genes related to neutrophil degranulation in vaccinated koalas during the first month post-vaccination. These findings show that vaccination of koalas while they are being treated with antibiotics for cystitis can result in the generation of a productive immune response, in the form of increased and expanded IgG production and host response through neutrophil degranulation.
View publication
View All Publications

更多信息

更多信息
Species Human
Contains Polypropylene tube containing an insert
Sample Source Bone Marrow, Whole Blood
Selection Method Negative
Legal Statement: SepMate™ (IVD) is only available in regions where it is registered as an In Vitro Diagnostic (IVD) device for the isolation of MNCs from whole blood or bone marrow by density gradient centrifugation. SepMate™ is manufactured under a cGMP quality managment system compliant to 21 CFR 820. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。